Cutaneous delayed-type hypersensitivity (DTH) in a multi-formulation comparator trial of the anti-falciparum malaria vaccine candidate RTS,S in rhesus macaques. (Q48034289)

From Wikidata

Jump to navigation Jump to search

scientific article published on 5 July 2006

Language	Label	Description	Also known as
English	Cutaneous delayed-type hypersensitivity (DTH) in a multi-formulation comparator trial of the anti-falciparum malaria vaccine candidate RTS,S in rhesus macaques.	scientific article published on 5 July 2006

Statements

scholarly article

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/16911849

Cutaneous delayed-type hypersensitivity (DTH) in a multi-formulation comparator trial of the anti-falciparum malaria vaccine candidate RTS,S in rhesus macaques. (English)

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/16911849

0 references

Plasmodium falciparum

0 references

malaria vaccine

1 reference

based on heuristic

inferred from title

D. Gray Heppner

10

object named as

D Gray Heppner

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/16911849

author name string

V Ann Stewart

1

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/16911849

Douglas S Walsh

2

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/16911849

Shannon M McGrath

3

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/16911849

Kent E Kester

4

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/16911849

James F Cummings

5

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/16911849

Gerald Voss

6

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/16911849

Martine Delchambre

7

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/16911849

Nathalie Garçon

8

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/16911849

Joe D Cohen

9

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/16911849

language of work or name

0 references

publication date

5 July 2006

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/16911849

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/16911849

24

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/16911849

42-43

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/16911849

6493-6502

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/16911849

Controlling malaria: challenges and solutions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.035

7 January 2021

Malaria: Current status of control, diagnosis, treatment, and a proposed agenda for research and development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.035

7 January 2021

The consequences of reducing transmission of Plasmodium falciparum in Africa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.035

7 January 2021

Forecasting, warning, and detection of malaria epidemics: a case study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.035

7 January 2021

The puzzling links between malaria transmission and drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.035

7 January 2021

Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.035

7 January 2021

Malaria vaccines in development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.035

7 January 2021

Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.035

7 January 2021

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.035

7 January 2021

Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.035

7 January 2021

Update on the clinical development of candidate malaria vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.035

7 January 2021

Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.035

7 January 2021

Cellular immunity induced by the recombinant Plasmodium falciparum malaria vaccine, RTS,S/AS02, in semi-immune adults in The Gambia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.035

7 January 2021

Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.035

7 January 2021

A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The Gambia.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.035

7 January 2021

Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.035

7 January 2021

Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.035

7 January 2021

Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.035

7 January 2021

Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.035

7 January 2021

Safety and immunogenicity of rts,s+trap malaria vaccine, formulated in the as02a adjuvant system, in infant rhesus monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.035

7 January 2021

Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.035

7 January 2021

Cutaneous delayed-type hypersensitivity responsiveness in patients during and after Plasmodium falciparum and Plasmodium vivax infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.035

7 January 2021

Delayed-type hypersensitivity skin testing using third variable loop peptides identifies T lymphocyte epitopes in human immunodeficiency virus-infected persons.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.035

7 January 2021

Delayed dermal hypersensitivity in rhesus monkeys (Macaca mulatta) immunized against Plasmodium knowlesi

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.035

7 January 2021

Delayed-type hypersensitivity in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum sporozoites.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.035

7 January 2021

An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.035

7 January 2021

Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.035

7 January 2021

Recruitment of lymphocytes during cutaneous delayed hypersensitivity in nonhuman primates is dependent on E-selectin and vascular cell adhesion molecule 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.035

7 January 2021

Non-human primates: a model for tuberculosis research

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.035

7 January 2021

Identifiers

10.1016/J.VACCINE.2006.06.035

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/16911849

release_emos5qwiq5gklezobbmvt6yclq

0 references

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/16911849

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48034289&oldid=1726615060"